ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

NCT05290090 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: Rituximab, Lenalidomide, Zanubrutinib and RCHOP

Sponsor

Zhejiang Cancer Hospital